36 results
8-K
EX-99.1
ADAP
Adaptimmune Therapeutics Plc
1 Jun 23
Adaptimmune Announces Completion of Strategic Combination with TCR² Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company
4:09pm
and their impact on Adaptimmune’s and TCR2’s respective businesses, operations, supply chain, patient enrollment and retention, preclinical and clinical trials
425
TCRR
Tcr2 Therapeutics Inc
30 May 23
Business combination disclosure
4:21pm
health crises and their impact on Adaptimmune’s and TCR2’s respective businesses, operations, supply chain, patient enrollment and retention
8-K
wqhtezxh81ltz9glq
30 May 23
Submission of Matters to a Vote of Security Holders
4:18pm
425
77cz abqhlnizv9t8
22 May 23
Business combination disclosure
7:01am
8-K
zeymifjp
22 May 23
Other Events
6:59am
8-K
EX-99.1
dm2901b5x mjs0orrt
12 May 23
Adaptimmune Reports First Quarter Financial Results and Business Update
7:36am
424B3
yysqp3y80tyul716
20 Apr 23
Prospectus supplement
4:32pm
S-4/A
om79 brc778hssiuc9
18 Apr 23
Registration of securities issued in business combination transactions (amended)
4:01pm
8-K
EX-10.1
zc5ou2 0lsaklam9
11 Apr 23
Adaptimmune and GSK Have Agreed Terms for Transfer of PRAME and NY-ESO Target Programs back to Adaptimmune
8:08am
S-4
g6csyy8vyucodqfmy9sa
5 Apr 23
Registration of securities issued in business combination transactions
4:40pm